Current stage -Stage II Posts on Medivizor
Navigation Menu

Current stage -Stage II Posts on Medivizor

Evaluating long-term outcomes after high-intensity focused ultrasound for prostate cancer

Evaluating long-term outcomes after high-intensity focused ultrasound for prostate cancer

Posted by on Feb 21, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients who underwent whole-gland high-intensity focused ultrasound (HIFU) for non-metastatic prostate cancer. The data showed that HIFU has favorable outcomes in low- and intermediate-risk groups of patients. Some background HIFU is a treatment option for prostate...

Read More

Evaluating long-term active surveillance for early-stage prostate cancer.

Evaluating long-term active surveillance for early-stage prostate cancer.

Posted by on Dec 28, 2020 in Prostate cancer | 0 comments

In a nutshell This study was carried out to assess the long-term outcomes of men diagnosed with prostate cancer (PC) undergoing active surveillance (AS) and factors that predicted the risk of their cancer spreading (metastasizing). The authors found that AS is a safe and viable option for men with low-risk and carefully-selected intermediate-risk...

Read More

Should patients with prostate cancer get androgen deprivation therapy before or after radiotherapy?

Should patients with prostate cancer get androgen deprivation therapy before or after radiotherapy?

Posted by on Dec 20, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness of giving androgen deprivation therapy (ADT) before or after radiotherapy (RT) for prostate cancer (PCa). The study found that treatment with RT followed by ADT increased patient survival without the spread of the disease. Some background PCa can often spread to other locations within the...

Read More

Comparing whole-pelvis vs prostate only radiotherapy in patients with high-risk prostate cancer

Comparing whole-pelvis vs prostate only radiotherapy in patients with high-risk prostate cancer

Posted by on Dec 6, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared the use of radiotherapy for prostate cancer in two areas: the prostate only, or the whole pelvis. The results showed that, for high-risk patients, radiotherapy of the whole pelvis improved patient outcomes. Some background For patients with medium or high-risk prostate cancer, the standard treatment is...

Read More

Are radiotherapy and surgery equally good at treating localized prostate cancer?

Are radiotherapy and surgery equally good at treating localized prostate cancer?

Posted by on Sep 26, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared surgery and radiotherapy for treating localized prostate cancer. They found no significant difference in survival between the two treatments. Some background Localized prostate cancer (cancer which has not spread beyond the prostate gland) can be treated with either surgery, radiotherapy, or monitoring without...

Read More

Comparing the effectiveness of apalutamide, darolutamide and enzalutamide in treating nonmetastatic castration-resistant prostate cancer

Comparing the effectiveness of apalutamide, darolutamide and enzalutamide in treating nonmetastatic castration-resistant prostate cancer

Posted by on Jul 26, 2020 in Prostate cancer | 0 comments

In a nutshell The study compared outcomes of apalutamide (A; Erleada), darolutamide (D; Nubeqa), and enzalutamide (E; Xtandi) in treating nonmetastatic castration-resistant prostate cancer (nmCRPC). The authors found that A and E had better metastasis-free survival (MFS) compared to D. Some background Men with CRPC fail to respond to...

Read More

Evaluating the risk of secondary cancers after internal radiation therapy in patients with prostate cancer

Evaluating the risk of secondary cancers after internal radiation therapy in patients with prostate cancer

Posted by on Jun 25, 2020 in Prostate cancer | 0 comments

In a nutshell This study looked at the long-term risk of secondary cancers following brachytherapy (BT; internal radiation therapy) for prostate cancer. It found that treating prostate cancer with BT had a low risk of secondary cancers. Some background Prostate cancer is a slow-growing cancer of the prostate gland. Men with prostate cancer that has...

Read More

Does enzalutmide improve survival in nonmetastatic, castration-resistant prostate cancer?

Does enzalutmide improve survival in nonmetastatic, castration-resistant prostate cancer?

Posted by on Jun 21, 2020 in Prostate cancer | 0 comments

In a nutshell The study assessed whether enzalutamide (Xtandi) plus androgen deprivation therapy (ADT) increased overall survival (OS) of patients with nonmetastatic, castration-resistant prostate cancer (CRPC). The study found improved survival in patients with CRPC treated with enzalutamide. Some background ADT is a type of hormonal therapy...

Read More

Should androgen-deprivation therapy be given at the same time or before radiotherapy in the treatment of localized prostate cancer?

Should androgen-deprivation therapy be given at the same time or before radiotherapy in the treatment of localized prostate cancer?

Posted by on Jun 11, 2020 in Prostate cancer | 0 comments

In a nutshell The study looked at the sequence of dose-escalated radiotherapy (RT) and androgen-deprivation therapy (ADT) in the treatment of local prostate cancer (LPCa). The study found that treatment with ADT before RT had the same outcome as treatment with ADT and RT at the same time.  Some background LPCa is a form of cancer that is...

Read More

Comparing cryosurgery and hormonal therapy for locally recurrent prostate cancer after radiotherapy

Comparing cryosurgery and hormonal therapy for locally recurrent prostate cancer after radiotherapy

Posted by on Jun 4, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared local cryosurgery (CRYO) against androgen deprivation therapy (ADT) for the treatment of locally recurring prostate cancer (LRPC). The study found local cryosurgery had a longer overall survival (OS) when compared to ADT. Some background LRPC is cancer that has re-occurred in the prostate gland...

Read More

Focal high-intensity focussed ultrasound for the treatment of localized prostate cancer

Posted by on Oct 5, 2019 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate the use of high-intensity focal ultrasound (HIFU) for the treatment of localized prostate cancer. This study found that HIFU is a safe treatment with good oncological results and minimal side-effects.  Some background High-intensity focused ultrasound (HIFU) is a non-invasive technique that uses...

Read More